Saliva is one of the important body fluids that reflects normal internal characteristics and
disease state of an individual. As a multi-composition oral fluid, has high potential for the …

Almost 80% of lung cancer diagnoses each year correspond to non-small cell lung cancer
(NSCLC). The percentage of NSCLC with EGFR overexpression ranges from 40% to 89 …

Acquired resistance remains a major barrier for the treatment of non-small cell lung cancer,
while cancer stem cells (CSCs) usually lead to the occurrence of drug resistance. We herein …

Introduction Patients with metastatic EGFR-mutant NSCLC inevitably have disease
progression while on tyrosine kinase inhibitor (TKI) therapy. Co-occurring tumor suppressor …

Lung cancer is the second most frequently diagnosed cancer type and responsible for the
highest number of cancer deaths worldwide. Lung adenocarcinoma (LUAD) and lung …

Background Epidermal growth factor receptor (EGFR) mutations (EGFR m) represent one of
the most common genomic alterations identified among patients with non-small cell lung …

Background Although immune checkpoint inhibitors (ICIs) generally show poor therapeutic
efficacy in patients with epidermal growth factor receptor (EGFR) mutations, certain research …

Abstract Background Personalized or Precision medicine (PM) is a promising approach for
the cancer treatment that tailors treatment to a patient's characteristics. Biomarkers are …

Objectives Mobocertinib, a novel oral epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor, is available for the treatment of non-small cell lung cancer (NSCLC) with …

Epidermal growth factor receptor (EGFR) is a prominent target for anticancer therapy due to
its role in activating several cell signaling cascades. Clinically approved EGFR inhibitors are …